Project Team

Kristell Lebozec, R&D Project Manager

Master of Biotechnology Engineering with a focus on R&D and Health. K. Lebozec has a 2 years experience in academic laboratories (Institut Gustave Roussy and Centre de Recherche des Cordeliers) and in the industry (DNA Therapeutics and I-Stem). She is in charge of selecting ACT017 expression system, designing analytical methods and of the functional characterization of products.

Laurie Jullien – Regulatory Affairs and Quality

PharmD., Master of International Development and Registration of Drugs. Laurie Jullien started at Genentech (USA) in Product Drug Development and was appointed Regulatory Affairs Labelling Manager at Roche (UK). She is in charge of the regulatory and quality strategy for the development of ACT017, the IMPD dossier and the clinical trial authorisation requests for phase 1 and 2.

 

Jean-Pierre Lehner – Cardiologist and Internal Medicine, Medical Affairs Consultant

MD., cardiologist and internal medicine graduate, Jean-Pierre Lehner served during 30 years the pharmaceutical industry. Appointed Senior Vice President & Chief Medical Officer at Sanofi in 2009, Jean-Pierre Lehner had responsibility for the worldwide medical affairs, regulatory affairs, safety and HEOR research including comparative effectiveness. Before joining pharmaceutical industry, he was head of the Intensive Care Unit of Cardiology in Hospital Bichat, Paris (France). He is now Executive Director of his own company (JPLPHARMA CONSULTING).

Frédéric Pailloux – Drug Development & Regulatory Science Consultant

Pharm.D and M.Sc. in Drug and Health Law, Senior Director at Voisin Consulting, Frederic is a Regulatory Science professional with 20+  years’ experience in the Pharmaceutical and Biotech industry. As Consultant, Frederic is actively involved in the design, preparation and management of registration applications, agency meetings and scientific advice procedures. Frederic provides support to Acticor Biotech for the development of regulatory strategies.

Olivier Loget – Non-clinical Development Consultant

DVM ERT, Eurotox registered toxicologist, CapEval Pharma CEO, Olivier Loget has worked more than 28 years in toxicology departments. Olivier was appointed Head of Non-Clinical Drug Safety Department at Addex in 2006 to participate in the IPO and to create, develop and lead this department until 2010, when he created CapEval Pharma and became cofounder and CSO of OriBase Pharma. Author or co-author of more than 20 publications, he is also cofounder of the European Society of Laboratory Animal Veterinarians and President of the International Society of Ocular Toxicology.